CYTO-202

N/A

Report date: 2022/04/21 09:44:10

Base Information

Drug NameCYTO-202

Drug Alias NameCYTO-202STAT-202

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionTyrosine-protein kinase receptor FLT3 modulators

TargetsTyrosine-protein kinase receptor FLT3

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesCytoImmune Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesCytoImmune Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A